Key result
SGLT2 inhibitors and GLP-1 receptor agonists appeared safe regarding renal and hepatic parameters over 12 months of follow-up in 405 patients with type 2 diabetes.
Why the study?
The study aimed to evaluate the safety of SGLT2 inhibitors and GLP-1 receptor agonists used alongside standard-of-care glucose-lowering drugs at maximum tolerated doses, and compared with metformin, in T2DM.
Are SGLT2 inhibitors and GLP-1 receptor agonists safe regarding renal and hepatic parameters when used in standard-of-care regimens for type 2 diabetes mellitus compared to baseline and metformin?
Observational (n=405)
No
Are SGLT2 inhibitors and GLP-1 receptor agonists safe regarding renal and hepatic parameters when used in standard-of-care regimens for type 2 diabetes mellitus compared to baseline and metformin?
SGLT2 inhibitors and GLP-1 receptor agonists demonstrate a safe renal and hepatic profile over 12 months in patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Supports real-world safety of SGLT2i/GLP-1 RAs with standard T2DM regimens; leaves open need for randomized confirmation.
AIM: We evaluated the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for their use with other glucose-lowering drugs and drugs for the treatment of type 2 diabetes mellitus (T2DM), in a standard-of-care regimen with maximum tolerated doses, and, respectively, when compared with metformin. METHODS: We conducted a retrospective, observational study on 405 patients that were seen in the outpatient clinic of the N Paulescu National Institute for Diabetes Mellitus, Bucharest, Romania, in 2019. Their demographics, metabolic parameters, and medication safety were evaluated at three follow-up visits, from baseline, six months, and twelve months. RESULTS: Both SGLT-2is and GLP-1 RAs are safe regarding creatinine, eGFR, urea, GOT, and GPT upon the comparison of the data from the six- and twelve-month visits with the initial visit, and also the twelve-month visit with the six-month visit. Moreover, when comparing SGLT-2is and GLP-1 RAs with metformin, there are safety data only for urea. CONCLUSIONS: In this retrospective analysis, both SGLT-2is and GLP-1 RAs, when used in conjunction with other glucose-lowering, blood-pressure-lowering, and lipid-lowering medications, appeared to be safe for the management of T2DM.
No takes yet. Share an insight, caveat, or question.
Salmen et al. (2023) conducted an observational in Type 2 diabetes mellitus (n=405). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) vs. Metformin was evaluated on Safety regarding creatinine, eGFR, urea, GOT, and GPT. SGLT2 inhibitors and GLP-1 receptor agonists appeared safe regarding renal and hepatic parameters over 12 months of follow-up in 405 patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: